Moloney Securities Asset Management’s INTEGRATED BIOPHARMA INC. INBP Stock Holding History

Moloney Securities Asset Management’s Portfolio INBP Stock Details INBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$5.8K	Hold	20,000	–	–	﹤0.01%	488
2025 Q2	$7.14K	Hold	20,000	–	–	﹤0.01%	486
2025 Q1	$5.6K	Hold	20,000	–	–	﹤0.01%	475
2024 Q4	$5.8K	Hold	20,000	–	–	﹤0.01%	461
2024 Q3	$4.69K	Hold	20,000	–	–	﹤0.01%	474
2024 Q2	$4.2K	Hold	20,000	–	–	﹤0.01%	461
2024 Q1	$3.85K	Hold	20,000	–	–	﹤0.01%	448
2023 Q4	$4.9K	Hold	20,000	–	–	﹤0.01%	439
2023 Q3	$5.6K	Hold	20,000	–	–	﹤0.01%	417
2023 Q2	$6.6K	Hold	20,000	–	–	﹤0.01%	409
2023 Q1	$7.66K	Hold	20,000	–	–	﹤0.01%	415
2022 Q4	$7.04K	Hold	20,000	–	–	﹤0.01%	386
2022 Q3	$9K	Hold	20,000	–	–	﹤0.01%	368
2022 Q2	$10K	Hold	20,000	–	–	﹤0.01%	361
2022 Q1	$16K	Hold	20,000	–	–	﹤0.01%	397
2021 Q4	$19K	Buy	+20,000	New	+$19K	﹤0.01%	431

Moloney Securities Asset Management's INBP Position: Q3 2025 in Review

Moloney Securities Asset Management held its INTEGRATED BIOPHARMA INC. (INBP) position steady in Q3 2025 at 20,000 shares worth $5.8K. The position accounts for ﹤0.01% of the portfolio, ranked #488.

Moloney Securities Asset Management first reported a position in INBP in Q4 2021 and has held it in 16 quarters since. The position peaked at $19K in Q4 2021. 1 fund tracked by Wall St. Rank holds INBP as of Q3 2025.

Moloney Securities Asset Management held 20,000 shares of INTEGRATED BIOPHARMA INC. worth $5.8K as of Q3 2025.
Moloney Securities Asset Management left its INTEGRATED BIOPHARMA INC. share count unchanged in Q3 2025.
INTEGRATED BIOPHARMA INC. made up ﹤0.01% of Moloney Securities Asset Management's portfolio in Q3 2025, its #488 holding.
Moloney Securities Asset Management first reported a position in INTEGRATED BIOPHARMA INC. in Q4 2021 and has held it in 16 quarters since.
Moloney Securities Asset Management's INTEGRATED BIOPHARMA INC. position peaked at $19K in Q4 2021.
1 fund tracked by Wall St. Rank held INTEGRATED BIOPHARMA INC. as of Q3 2025.

Based on Moloney Securities Asset Management's 13F filing for Q3 2025, filed 5 Nov 2025.